obstructive sleep apnea in highlanders
Conditions
Interventions
Acetazolamide group (Tibetan):Acetazolamide
Placebo group (Tibetan):Placebo
Acetazolamide group (Han):Acetazolamide
Placebo group (Han):Placebo
Sponsors
Sleep Medicine Center, West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Both sexes, aged 30-60 years, Tibetan and Han ethnicity 2. Tibetans should be living at an elevation of 3650 m for over 10 years or born and living at an elevation of 3650 m; Hans should be living at an elevation of 3650 m for over 5 years or born and living at an elevation of 3650 m 3. An AHI of over 15 /h according to baseline PSG during a screening evaluation
Exclusion criteria
Exclusion criteria: 1. Unstable cardiovascular disease, such as angina, coronary heart disease, hypertension (systolic pressure >160 mmHg, diastolic pressure >100 mmHg) and atrial fibrillation, uncontrolled diabetes and previous stroke 2. Taking antihypertensive medication, receiving continuous positive airway pressure therapy or mandible advancement therapy currently 3. History of surgery such as uvulopalatopharyngoplasty (UPPP) to relieve OSA 4. Exposed to lower altitude (altitude 5000 m) in the previous half year for more than 1 week 5. History of chronic respiratory disease and/or chronic hypercapnia respiratory failure, such as chronic obstructive pulmonary disease (FEV1/FVC6kPa) 6. Liver dysfunction (ALT and AST over 2-fold of upper limit value), renal dysfunction (eGFR<50 ml/min/1.73m2), previous history of renal calculi 7. Chronic mountain sickness (Qinghai CMS score over 6) 8. History of allergy to sulfanilamide or sulfanilamide derivatives or taking concomitant medication that may interfere with acetazolamide (i.e. high dose of acetylsalicylic acid) 9. Other sleep disorders, such as insomnia, narcolepsy, restless leg syndrome, rapid eye movement behavior disorder and so on 10. Pregnancy or lactation 11. Internal, neurologic or psychiatric disease that may prevent compliance with the protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24-hour mean blood pressure; | — |
Secondary
| Measure | Time frame |
|---|---|
| Apnea-hypopnea index;Mean nocturnal oxygen saturation;Oxygen desaturation index;24-hour systolic and diastolic blood pressure;Daytime mean blood pressure;Daytime systolic and diastolic blood pressure;Nighttime systolic and diastolic blood pressure;Sleep quality and sleep structure;PVT response speed;Cerebral tissue oxygenation and desaturation;ECG changes and QTc duration;Nocturnal hypoxic burden;Overnight fluid shift; | — |
Countries
China
Contacts
Public ContactTang Xiangdong
Sleep Medicine Center, West China Hospital, Sichuan University
Outcome results
None listed